Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Revenue of Benitec Biopharma Inc. (BNTC)
Revenue in 2024 (TTM): $216 K
According to Benitec Biopharma Inc.'s latest financial reports the company's current revenue (TTM) is $216 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Benitec Biopharma Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $216 K | $108 K | $-22,490,000 | $-22,370,000 | $-21,751,000 |
| 2023 | $75 K | $-306,000 | $-18,700,000 | $-19,562,000 | $-19,562,000 |
| 2022 | $73 K | $64 K | $-17,854,000 | $-18,208,000 | $-18,562,000 |
| 2021 | $59 K | $-64,000 | $-13,596,000 | $-13,882,000 | $-13,781,000 |
| 2020 | $97 K | $-171,065 | $-7,907,000 | $-8,274,000 | $-8,301,000 |
| 2019 | $11.32 M | $10.89 M | $2.74 M | $2.87 M | $2.87 M |
| 2018 | $455.45 K | $124.15 K | $-8,587,380 | $-8,550,650 | $-8,550,650 |
| 2017 | $450.31 K | $241.29 K | $-4,190,361 | $-4,372,483 | $-4,372,483 |
| 2016 | $346.51 K | $242.7 K | $-13,418,168 | $-18,503,749 | $-18,503,749 |
| 2015 | $829.13 K | $798.45 K | $-7,931,553 | $-8,827,410 | $-8,827,410 |
| 2014 | $1.02 M | $980.1 K | $-9,897,942 | $-10,835,671 | $-10,835,671 |
| 2013 | $545.73 K | $369.6 K | $-6,635,517 | $-6,838,114 | $-6,423,793 |